The company is advancing DT120 ODT (lysergide tartrate) for MDD, GAD, and PTSD. Three pivotal clinical trial readouts are expected within the next six months: Emerge (MDD) in late 2Q 2026, Voyage (GAD) in early 3Q 2026, and Panorama (GAD) in late 3Q 2026. The Phase 3 Haven study for PTSD is expected to initiate in 2027. The company reported a strong financial position with $411.6 million in cash, cash equivalents, and investments as of December 31, 2025, providing a runway into 2028. The commercial strategy focuses on a scalable delivery model and leveraging existing administrative pathways for reimbursement.